Skip to main content
. 2019 Dec 10;24(2):1822–1836. doi: 10.1111/jcmm.14879

Figure 4.

Figure 4

p38MAPK contributes to lovastatin‐induced p53 activation, p21 elevation and survivin reduction in MCF‐7 cells. A, Cells were treated with vehicle or lovastatin at 30 μmol/L for indicated periods. The extent of p38MAPK phosphorylation (MW 38 kD) was examined by immunoblotting. Each column represents the mean ± SEM of six independent experiments (Statistically significant differences were determined using the Kruskal‐Wallis test. *P < .05, compared with the control group). Cells were pre‐treated with p38MAPK inhibitor III (p38i) at 1 μmol/L for 30 min. After treatment, cells were stimulated with lovastatin at 30 μmol/L for another 24 h. Protein levels of p21 (B) or survivin (C) were determined by immunoblotting. Each column represents the mean ± SEM of six independent experiments (Statistically significant differences were determined using the Mann‐Whitney test. *P < .05, compared with the vehicle‐treated control group; # P < .05, compared with the group treated with lovastatin alone). D, Cells were pre‐treated with p38MAPK inhibitor III (p38i) at 1 μmol/L for 30 min. After treatment, cells were stimulated with lovastatin at 30 μmol/L for another 1 h. The extent of p53 phosphorylation was determined by immunoblotting. Each column represents the mean ± SEM of six independent experiments (Statistically significant differences were determined using the Mann‐Whitney test. *P < .05, compared with the vehicle‐treated control group; # P < .05, compared with the group treated with lovastatin alone). (E) Cells were transiently transfected with PG13‐luc (p53‐luc) plus renilla‐luc for 24 h. After transfection, cells were pre‐treated with p38MAPK inhibitor III (p38i) at 1 μmol/L for 30 min followed by the stimulant with lovastatin (30 μmol/L) for another 24 h. Reporter assay was performed as described in the ‘Materials and Methods’ section. Each column represents the mean ± SEM of five independent experiments (Statistically significant differences were determined using the Mann‐Whitney test. *P < .05, compared with the vehicle‐treated control group; # P < .05, compared with the group treated with lovastatin alone)

HHS Vulnerability Disclosure